Table 4 Previous medication during COVID treatment period
From: Risk factors affecting outcome of rhino-orbital-cerebral mucormycosis in COVID-19 patients
Duration between COVID-19 infection and start of mucormycosis | |
|---|---|
 Median (IQR) | 30 (21–60) |
 Range | 7–90 |
Steroids dose | 29 (88%) |
Anti-IL-6 actemra (tocilizumab) | 6 (18.2%) |
Antiviral (remdesivir) | 6 (18.2%) |